NASDAQ: KLRS
Kalaris Therapeutics Inc Stock Ownership - Who owns Kalaris Therapeutics?

Insider buying vs selling

Have Kalaris Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Srinivas AkkarajuDirector2025-12-221,500,000$10.00
$15.00MBuy
Srinivas AkkarajuDirector2025-12-18479,847$10.42
$5.00MBuy
Brett R. HagenChief Accounting Officer2025-03-26907$8.97
$8.13kSell

1 of 1

KLRS insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when KLRS insiders and whales buy or sell their stock.

KLRS Shareholders

What type of owners hold Kalaris Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Morana Jovanembiricos425.09%79,502,507$795.03MInsider
David Hallal372.69%69,701,844$697.02MInsider
Vikas Sinha182.46%34,123,650$341.24MInsider
Ansbert Gadicke161.08%30,125,933$301.26MInsider
Elevatebio LLC89.16%16,674,766$166.75MInsider
Gilead Sciences Inc88.95%16,635,286$166.35MInsider
Samsara Biocapital LLC69.23%12,948,081$129.48MInstitution
Srinivas Akkaraju66.69%12,471,812$124.72MInsider
Samsara Biocapital GP LLC61.21%11,448,081$114.48MInsider
F2 Mg Ltd52.55%9,828,091$98.28MInsider

1 of 3

KLRS vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
KLRS5.69%94.31%Net BuyingNet Buying
MOLN9.60%0.00%
GALT13.13%86.87%Net SellingNet Selling
NTHI10.18%89.82%Net BuyingNet Buying
RNAC11.19%88.81%Net BuyingNet Buying

Kalaris Therapeutics Stock Ownership FAQ

Who owns Kalaris Therapeutics?

Kalaris Therapeutics (NASDAQ: KLRS) is owned by 96.22% institutional shareholders, 1,595.31% Kalaris Therapeutics insiders, and 0.00% retail investors. Morana Jovanembiricos is the largest individual Kalaris Therapeutics shareholder, owning 79.50M shares representing 425.09% of the company. Morana Jovanembiricos's Kalaris Therapeutics shares are currently valued at $795.03M.

If you're new to stock investing, here's how to buy Kalaris Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.